SEC Form 4																
FOR	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549												OMB APPROVAL			
 Section 16. Form obligations may or Instruction 1(b). Check this box to transaction was r contract, instruction the purchase or sections. 	indicate that a nade pursuant to a on or written plan for ale of equity ssuer that is intended mative defense	STATI	Filed p	ursuan	it to Sectio	on 16(ES IN B	curitie	es Exchai	nge Act of		SHIP	Estin	Numbenated av	verage burde	3235-0287 in 0.5
1. Name and Address Garner Thom (Last)	* (Middle)	<u>A</u>	2. Issuer Name and Ticker or Trading Symbol <u>ACADIA PHARMACEUTICALS I</u> ACAD]								5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director 10% Owner Officer (give title Other (specify below) DUD (chic Communic Low)				wner specify	
C/O ACADIA PHARMACEUTICALS, INC. 12830 EL CAMINO REAL, SUITE 400				 3. Date of Earliest Transaction (Month/Day/Year) 12/09/2024 4. If Amendment, Date of Original Filed (Month/Day/Year) 								EVP, Chief Commercial Officer 6. Individual or Joint/Group Filing (Check Applicable				
(Street) SAN DIEGO	92130										Line) Form filed by One Reporting Person Form filed by More than One Reporting Person					
(City)	(State)	(Zip)							<u> </u>							
1. Title of Security (Instr. 3) 2. Transa Date				ative Securities Ac action Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Yea			ar) 3. Transact Code (In 8)	tion	4. Securities Acquire on Disposed Of (D) (Inst		red (A) or str. 3, 4 an	5. Amou	s ally ollowing I ion(s)	(s) Form: Dir (D) or Ind (I) (Instr. 4		7. Nature of Indirect Beneficial Ownership (Instr. 4)
		Table II - De					uired, Dis			•		Owned		1		
1. Title of Derivative Security (Instr. 3) 2. Convers or Exerc Price of Derivativ Security	ise (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea	e, 4. Transa Code	action	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		, , ,		ble and	7. Title and Amour of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Numb derivativ Securitie Benefici Owned Followin Reported Transact	ve es ally Ig d	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership t (Instr. 4)
			Code	v	(A)	(D)	Date Exercisable		xpiration ate	Title	Amount or Number of Share	5	(Instr. 4)			
Stock Option (Right to Buy) \$18.70	5 12/09/2024		Α		235,849		(1)	12	2/08/2034	Common Stock	235,84	9 \$0	235,8	5,849 D		
Restricted Stock (2) Explanation of Res	12/09/2024		Α		45,372		(3)		(3)	Common Stock	45,372	\$0	\$0 45,37		D	

1. 25% of the shares subject to the Stock Option granted under the 2024 Equity Incentive Plan (the "Plan") will vest and become exercisable on December 9, 2025. The remaining shares vest and become exercisable in 36 equal monthly installments thereafter.

2. Each restricted stock unit granted under the Plan represents a contingent right to receive one share of the Issuer's common stock.

3. 50% of the restricted stock units vest on December 9, 2026 and 25% vest on each of December 9, 2027 and December 9, 2028.

/s/ Jennifer J. Rhodes, Attorney-12/10/2024

in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.